Northwest Biotherapeutics, Inc Stock OTC Bulletin Board
Equities
US66737P5017
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
May. 10 | Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 21 | Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors | CI |
Financials (USD)
Sales 2022 | 1.68M | Sales 2023 | 1.93M | Capitalization | 822M |
---|---|---|---|---|---|
Net income 2022 | -105M | Net income 2023 | -62M | EV / Sales 2022 | 505 x |
Net Debt 2022 | 19.29M | Net Debt 2023 | 43.43M | EV / Sales 2023 | 448 x |
P/E ratio 2022 |
-7.59
x | P/E ratio 2023 |
-11.7
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.82% |
Managers | Title | Age | Since |
---|---|---|---|
Linda F. Powers
CEO | Chief Executive Officer | 68 | 07-05-16 |
Alton L. Boynton
FOU | Founder | 79 | 96-03-17 |
Marnix L. Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 99-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alton L. Boynton
FOU | Founder | 79 | 96-03-17 |
Linda F. Powers
CEO | Chief Executive Officer | 68 | 07-05-16 |
Navid Malik
BRD | Director/Board Member | 55 | 12-03-31 |
1st Jan change | Capi. | |
---|---|---|
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-3.99% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |